Abstract
Objectives: To characterize objective sleep patterns among U.S. adults before and during the COVID-19 pandemic, and to assess for associations between adverse mental health symptoms and (1) sleep duration and (2) the consistency of sleep timing before and during the pandemic. Design: Longitudinal objective sleep-wake data during January-June 2020 were linked with mental health and substance use assessments conducted during June 2020 for The COVID-19 Outbreak Public Evaluation (COPE) Initiative. Setting: Adult users of WHOOP—a commercial, digital sleep wearable. Participants: Adults residing in the U.S. and actively using WHOOP wearable devices, recruited by WHOOP, Inc. Intervention: The COVID-19 pandemic and its mitigation. Measurements: Anxiety or depression symptoms, burnout symptoms, and new or increased substance use to cope with stress or emotions. Results: Of 4912 participants in the primary analytic sample (response rate, 14.9%), we observed acutely increased sleep duration (0.25 h or 15 m) and sleep consistency (3.51 points out of 100) and delayed sleep timing (onset, 18.7 m; offset, 36.6 m) during mid-March through mid-April 2020. Adjusting for demographic and lifestyle variables, participants with persistently insufficient sleep duration and inconsistent sleep timing had higher odds of adverse mental health symptoms and substance use in June 2020. Conclusions: U.S. adult wearable users displayed increased sleep duration, more consistent sleep timing, and delayed sleep onset and offset times after the COVID-19 pandemic onset, with subsample heterogeneity. Associations between adverse mental health symptoms and pre- and mid-pandemic short sleep duration and inconsistent sleep timing suggest that these characteristics warrant further investigation as potential modifiable mental health and substance use risk factors.
Original language | English |
---|---|
Pages (from-to) | 311-321 |
Number of pages | 11 |
Journal | Sleep Health |
Volume | 8 |
Issue number | 3 |
DOIs | |
Publication status | Published - Jun 2022 |
Keywords
- Anxiety
- Coronavirus
- Depression
- Epidemiology
- Substance use
- Wearable
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Prior sleep-wake behaviors are associated with mental health outcomes during the COVID-19 pandemic among adult users of a wearable device in the United States. / Czeisler, Mark; Capodilupo, Emily R.; Weaver, Matthew D. et al.
In: Sleep Health, Vol. 8, No. 3, 06.2022, p. 311-321.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Prior sleep-wake behaviors are associated with mental health outcomes during the COVID-19 pandemic among adult users of a wearable device in the United States
AU - Czeisler, Mark
AU - Capodilupo, Emily R.
AU - Weaver, Matthew D.
AU - Czeisler, Charles A.
AU - Howard, Mark E.
AU - Rajaratnam, Shantha M.W.
N1 - Funding Information: There was no specific funding for survey data collection. Mr Czeisler was supported in part by a 2020 Australian-American Fulbright Scholarship funded by The Kinghorn Foundation, and by a grant from WHOOP, Inc., to Monash University acting through its Faculty of Medicine, Nursing and Health Sciences. Dr Czeisler is the incumbent of an endowed professorship provided to Harvard University by Cephalon, Inc. Funding Information: There was no specific funding for survey data collection. Mr Czeisler was supported in part by a 2020 Australian-American Fulbright Scholarship funded by The Kinghorn Foundation , and by a grant from WHOOP, Inc., to Monash University acting through its Faculty of Medicine, Nursing and Health Sciences . Dr Czeisler is the incumbent of an endowed professorship provided to Harvard University by Cephalon, Inc. Funding Information: Mr Czeisler and Drs Weaver, Czeisler, Howard, and Rajaratnam reported receiving a grant from the CDC Foundation with funding from BNY Mellon, a grant from WHOOP, Inc., and a gift from Hopelab, Inc. Mr Czeisler reported having received a grant from the Australian-American Fulbright Commission administered through a 2020 to 2021 Fulbright Scholarship funded by The Kinghorn Foundation and having received personal fees from Vanda Pharmaceuticals. Ms Capodilupo is a paid employee of and has equity interest in WHOOP, Inc., and has equity interest in ARCHANGELS. Dr Weaver reported consulting fees from National Sleep Foundation and the University of Pittsburgh. Dr Czeisler reported receiving grants to support The COVID-19 Outbreak Public Evaluation (COPE) Initiative and grants from Brigham and Women's Physician's Organization during the conduct of the study; being a paid consultant to or speaker for Ganésco, Institute of Digital Media and Child Development, Klarman Family Foundation, M. Davis and Co, Physician's Seal, Samsung Group, State of Washington Board of Pilotage Commissioners, Tencent Holdings, Teva Pharma Australia, and Vanda Pharmaceuticals, in which Dr Czeisler holds an equity interest; receiving travel support from Aspen Brain Institute, Bloomage International Investment Group, UK Biotechnology and Biological Sciences Research Council, Bouley Botanical, Dr Stanley Ho Medical Development Foundation, Illuminating Engineering Society, National Safety Council, Tencent Holdings, and The Wonderful Co; receiving institutional research and/or education support from Cephalon, Mary Ann and Stanley Snider via Combined Jewish Philanthropies, Harmony Biosciences, Jazz Pharmaceuticals PLC, Johnson and Johnson, Neurocare, Peter Brown and Margaret Hamburg, Philips Respironics, Regeneron Pharmaceuticals, Regional Home Care, Teva Pharmaceuticals Industries, Sanofi S.A., Optum, ResMed, San Francisco Bar Pilots, Schneider National, Serta, Simmons Betting, Sysco, Vanda Pharmaceuticals; being or having been an expert witness in legal cases, including those involving Advanced Power Technologies; Aegis Chemical Solutions; Amtrak; Casper Sleep; C and J Energy Services; Complete General Construction; Dallas Police Association; Enterprise Rent-A-Car; Steel Warehouse Co; FedEx; Greyhound Lines; Palomar Health District; PAR Electrical, Product, and Logistics Services; Puckett Emergency Medical Services; South Carolina Central Railroad Co; Union Pacific Railroad; UPS; and Vanda Pharmaceuticals; serving as the incumbent of an endowed professorship provided to Harvard University by Cephalon; and receiving royalties from McGraw Hill and Philips Respironics for the Actiwatch-2 and Actiwatch Spectrum devices. Dr Czeisler's interests were reviewed and are managed by the Brigham and Women's Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. Dr Rajaratnam reported receiving institutional consulting fees from CRC for Alertness, Safety, and Productivity; Teva Pharmaceuticals; Vanda Pharmaceuticals; Circadian Therapeutics; BHP Billiton; and Herbert Smith Freehills; receiving grants from Teva Pharmaceuticals and Vanda Pharmaceuticals; and serving as chair for the Sleep Health Foundation outside the submitted work. Dr Howard reports receiving institutional consulting fees from Teva Pharmaceuticals, Biogen and Sanofi; and equipment to support research from Optalert and Philips Respironics outside the submitted work. No other potential conflicts of interest were reported. Publisher Copyright: © 2022
PY - 2022/6
Y1 - 2022/6
N2 - Objectives: To characterize objective sleep patterns among U.S. adults before and during the COVID-19 pandemic, and to assess for associations between adverse mental health symptoms and (1) sleep duration and (2) the consistency of sleep timing before and during the pandemic. Design: Longitudinal objective sleep-wake data during January-June 2020 were linked with mental health and substance use assessments conducted during June 2020 for The COVID-19 Outbreak Public Evaluation (COPE) Initiative. Setting: Adult users of WHOOP—a commercial, digital sleep wearable. Participants: Adults residing in the U.S. and actively using WHOOP wearable devices, recruited by WHOOP, Inc. Intervention: The COVID-19 pandemic and its mitigation. Measurements: Anxiety or depression symptoms, burnout symptoms, and new or increased substance use to cope with stress or emotions. Results: Of 4912 participants in the primary analytic sample (response rate, 14.9%), we observed acutely increased sleep duration (0.25 h or 15 m) and sleep consistency (3.51 points out of 100) and delayed sleep timing (onset, 18.7 m; offset, 36.6 m) during mid-March through mid-April 2020. Adjusting for demographic and lifestyle variables, participants with persistently insufficient sleep duration and inconsistent sleep timing had higher odds of adverse mental health symptoms and substance use in June 2020. Conclusions: U.S. adult wearable users displayed increased sleep duration, more consistent sleep timing, and delayed sleep onset and offset times after the COVID-19 pandemic onset, with subsample heterogeneity. Associations between adverse mental health symptoms and pre- and mid-pandemic short sleep duration and inconsistent sleep timing suggest that these characteristics warrant further investigation as potential modifiable mental health and substance use risk factors.
AB - Objectives: To characterize objective sleep patterns among U.S. adults before and during the COVID-19 pandemic, and to assess for associations between adverse mental health symptoms and (1) sleep duration and (2) the consistency of sleep timing before and during the pandemic. Design: Longitudinal objective sleep-wake data during January-June 2020 were linked with mental health and substance use assessments conducted during June 2020 for The COVID-19 Outbreak Public Evaluation (COPE) Initiative. Setting: Adult users of WHOOP—a commercial, digital sleep wearable. Participants: Adults residing in the U.S. and actively using WHOOP wearable devices, recruited by WHOOP, Inc. Intervention: The COVID-19 pandemic and its mitigation. Measurements: Anxiety or depression symptoms, burnout symptoms, and new or increased substance use to cope with stress or emotions. Results: Of 4912 participants in the primary analytic sample (response rate, 14.9%), we observed acutely increased sleep duration (0.25 h or 15 m) and sleep consistency (3.51 points out of 100) and delayed sleep timing (onset, 18.7 m; offset, 36.6 m) during mid-March through mid-April 2020. Adjusting for demographic and lifestyle variables, participants with persistently insufficient sleep duration and inconsistent sleep timing had higher odds of adverse mental health symptoms and substance use in June 2020. Conclusions: U.S. adult wearable users displayed increased sleep duration, more consistent sleep timing, and delayed sleep onset and offset times after the COVID-19 pandemic onset, with subsample heterogeneity. Associations between adverse mental health symptoms and pre- and mid-pandemic short sleep duration and inconsistent sleep timing suggest that these characteristics warrant further investigation as potential modifiable mental health and substance use risk factors.
KW - Anxiety
KW - Coronavirus
KW - Depression
KW - Epidemiology
KW - Substance use
KW - Wearable
UR - http://www.scopus.com/inward/record.url?scp=85132228111&partnerID=8YFLogxK
U2 - 10.1016/j.sleh.2022.03.001
DO - 10.1016/j.sleh.2022.03.001
M3 - Article
C2 - 35459638
AN - SCOPUS:85132228111
VL - 8
SP - 311
EP - 321
JO - Sleep Health
JF - Sleep Health
SN - 2352-7218
IS - 3
ER -